Egyptian International Pharmaceutical Industries Future Growth
Future criteria checks 3/6
Egyptian International Pharmaceutical Industries is forecast to grow earnings and revenue by 14.2% and 15.3% per annum respectively.
Key information
14.2%
Earnings growth rate
n/a
EPS growth rate
Pharmaceuticals earnings growth | 17.9% |
Revenue growth rate | 15.3% |
Future return on equity | 20.5% |
Analyst coverage | Low |
Last updated | 06 Mar 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 8,890 | N/A | 1,211 | 616 | 2 |
12/31/2025 | 7,592 | 1,085 | 1,082 | 241 | 2 |
12/31/2024 | 6,185 | 874 | 330 | 456 | 2 |
12/31/2023 | 5,232 | 822 | -2,200 | 90 | N/A |
9/30/2023 | 4,949 | 869 | -2,493 | -227 | N/A |
3/31/2023 | 4,020 | 658 | -1,268 | -316 | N/A |
12/31/2022 | 3,955 | 643 | -860 | -297 | N/A |
9/30/2022 | 3,648 | 581 | -555 | 73 | N/A |
6/30/2022 | 3,623 | 544 | 123 | 594 | N/A |
3/31/2022 | 3,551 | 494 | 83 | 534 | N/A |
12/31/2021 | 3,409 | 488 | -53 | 384 | N/A |
9/30/2021 | 3,171 | 472 | 207 | 426 | N/A |
6/30/2021 | 2,978 | 461 | -263 | -77 | N/A |
3/31/2021 | 2,901 | 465 | -574 | -368 | N/A |
12/31/2020 | 2,886 | 487 | -39 | 165 | N/A |
9/30/2020 | 2,969 | 488 | -736 | -517 | N/A |
6/30/2020 | 3,113 | 534 | -233 | -1 | N/A |
3/31/2020 | 3,266 | 641 | 436 | 652 | N/A |
12/31/2019 | 3,411 | 671 | 103 | 280 | N/A |
9/30/2019 | 3,294 | 731 | 509 | 675 | N/A |
6/30/2019 | 3,126 | 711 | 270 | 411 | N/A |
3/31/2019 | 2,999 | 735 | -268 | -125 | N/A |
12/31/2018 | 2,816 | 701 | -142 | -12 | N/A |
9/30/2018 | 2,784 | 611 | -131 | -17 | N/A |
6/30/2018 | 2,767 | 688 | -54 | 55 | N/A |
3/31/2018 | 2,654 | 714 | 56 | 156 | N/A |
12/31/2017 | 2,527 | 688 | 125 | 209 | N/A |
9/30/2017 | 2,372 | 671 | N/A | 400 | N/A |
6/30/2017 | 2,210 | 642 | N/A | 395 | N/A |
3/31/2017 | 2,079 | 522 | N/A | 629 | N/A |
12/31/2016 | 1,969 | 487 | N/A | 641 | N/A |
9/30/2016 | 1,873 | 466 | N/A | 548 | N/A |
6/30/2016 | 1,793 | 448 | N/A | 541 | N/A |
3/31/2016 | 1,745 | 427 | N/A | 453 | N/A |
12/31/2015 | 1,697 | 393 | N/A | 403 | N/A |
9/30/2015 | 1,682 | 403 | N/A | 434 | N/A |
6/30/2015 | 1,646 | 340 | N/A | 399 | N/A |
3/31/2015 | 1,624 | 333 | N/A | 345 | N/A |
12/31/2014 | 1,578 | 342 | N/A | 301 | N/A |
9/30/2014 | 1,528 | 340 | N/A | 208 | N/A |
6/30/2014 | 1,453 | 332 | N/A | 201 | N/A |
3/31/2014 | 1,397 | 325 | N/A | 250 | N/A |
12/31/2013 | 1,357 | 330 | N/A | 205 | N/A |
9/30/2013 | 1,319 | 306 | N/A | 264 | N/A |
6/30/2013 | 1,303 | 304 | N/A | 276 | N/A |
3/31/2013 | 1,292 | 320 | N/A | 274 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PHAR's forecast earnings growth (14.2% per year) is above the savings rate (14%).
Earnings vs Market: PHAR's earnings (14.2% per year) are forecast to grow slower than the EG market (15.3% per year).
High Growth Earnings: PHAR's earnings are forecast to grow, but not significantly.
Revenue vs Market: PHAR's revenue (15.3% per year) is forecast to grow faster than the EG market (14.1% per year).
High Growth Revenue: PHAR's revenue (15.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PHAR's Return on Equity is forecast to be high in 3 years time (20.5%)